Genome sequencing can identify individuals in the general population who harbor rare coding variants in genes for Mendelian disorders 1-7 and who may consequently have increased disease risk. Previous studies of rare variants in phenotypically extreme individuals display ascertainment bias and may demonstrate inflated effect-size estimates 8-12 . We sequenced seven genes for maturity-onset diabetes of the young (MODY) 13 in well-phenotyped population samples 14,15 (n = 4,003). We filtered rare variants according to two prediction criteria for disease-causing mutations: reported previously in MODY or satisfying stringent de novo thresholds (rare, conserved and protein damaging). Approximately 1.5% and 0.5% of randomly selected individuals from the Framingham and Jackson Heart Studies, respectively, carry variants from these two classes. However, the vast majority of carriers remain euglycemic through middle age. Accurate estimates of variant effect sizes from population-based sequencing are needed to avoid falsely predicting a substantial fraction of individuals as being at risk for MODY or other Mendelian diseases.
l e t t e r s
Genome sequencing can identify individuals in the general population who harbor rare coding variants in genes for Mendelian disorders [1] [2] [3] [4] [5] [6] [7] and who may consequently have increased disease risk. Previous studies of rare variants in phenotypically extreme individuals display ascertainment bias and may demonstrate inflated effect-size estimates [8] [9] [10] [11] [12] . We sequenced seven genes for maturity-onset diabetes of the young (MODY) 13 in well-phenotyped population samples 14, 15 (n = 4,003). We filtered rare variants according to two prediction criteria for disease-causing mutations: reported previously in MODY or satisfying stringent de novo thresholds (rare, conserved and protein damaging). Approximately 1.5% and 0.5% of randomly selected individuals from the Framingham and Jackson Heart Studies, respectively, carry variants from these two classes. However, the vast majority of carriers remain euglycemic through middle age. Accurate estimates of variant effect sizes from population-based sequencing are needed to avoid falsely predicting a substantial fraction of individuals as being at risk for MODY or other Mendelian diseases.
For personal genome sequencing to help identify at-risk individuals for preventative care [1] [2] [3] [4] [5] [6] [7] , the ascertainment bias typically employed in human genetic research presents a double-edged sword: studying individuals with an extreme phenotype has efficiently identified disease variants but has also introduced an upwards bias in reported effect sizes [10] [11] [12] . Examples include an initial inflation of reported BRCA1 and BRCA2 (breast cancer, MIM114480) 8, 16 and HFE (hereditary hemochromatosis, MIM235200) 9 mutation penetrance that was remedied once adequately sized population-based control groups were studied. Absent similar studies for other diseases, widespread personal genomic testing might exaggerate risk estimates, instigating needless intervention in low-risk individuals 1, 2, 6, 17 .
MODY (MIM606391) 18, 19 is a good candidate for personal genomic screening for several reasons: (i) it is caused by dominant Mendelian mutations, such that heterozygous carriers develop disease 20 ; (ii) clinical presentation occurs early in life (<25 years) with nonketotic hyperglycemia 18, 19 ; (iii) the frequency of MODY is 0.1-0.2% in European populations 21, 22 , with the majority of affected individuals being undiagnosed or misdiagnosed 23 ; (iv) MODY diagnosis Assessing the phenotypic effects in the general population of rare variants in genes for a dominant Mendelian form of diabetes l e t t e r s can substantially affect diabetes prognosis and treatment 24, 25 of the individual or affected family members 26 ; (v) mutations in MODY genes also influence late-onset phenotypes, as common variants near many of these genes are associated with type 2 diabetes (T2D) risk in the general population 27 ; and (vi) this risk can be reduced by lifestyle intervention 28, 29 . Thus, individuals identified through personal genomics to carry variants in MODY genes might be anticipated to exhibit elevated glycemic parameters by young adulthood, or by middle age at minimum, and could benefit from early intervention.
We aimed to characterize the spectrum of low-frequency variation in MODY genes in the general population. Specifically, how many individuals carry rare variants in MODY genes of the sort that might be bioinformatically flagged in a personal genome sequencing context, and what percentage of these carriers demonstrate an abnormal glycemic phenotype by middle age? In addition to studying randomly ascertained individuals from population cohorts, we validated our methods using individuals selected for MODY or T2D diagnosis.
We focused on seven genes: the four that are most frequently mutated (HNF1A 30 , GCK 31, 32 , HNF4A 33 and HNF1B 34 ) and three that are less frequently mutated (PDX1 (ref. 35) , INS 36 and NEUROD1 (ref. 37)) in European patients with MODY. We did not study six other MODY genes, two because loss of function in these genes causes hypoglycemia rather than diabetes (ABCC8 and KCNJ11) 38 and four because sequence data were unavailable (PAX4 (ref. 39) , BLK 40 , KLF11 (ref. 41) and CEL 42 ; Online Methods).
Our primary analysis focused on 4,003 individuals drawn from three population-based cohorts (Table 1) . First, we randomly ascertained 1,541 individuals of European ancestry from the Framingham Heart Study Offspring cohort 14 (FHS cohort) and 1,691 individuals of African-American ancestry from the Jackson Heart Study (JHS cohort) 15 ; these individuals are referred to as 'unselected' (Supplementary Figs. 1-3) . Second, from Finnish and Swedish cohorts (>27,500 individuals), we ascertained 771 individuals from the extremes of T2D genetic risk (T2D cohort; 362 young lean individuals with T2D and 409 elderly obese euglycemic controls 11 ); these individuals are referred to as 'extreme' (Supplementary Figs. 1 and 3-5 and Online Methods). We used target capture and DNA sequencing 43 of the seven analyzed genes (Online Methods) to identify sequence variants; >93% of bases were covered with at least 20 reads in all genes except INS (79.1%) and PDX1 (37.7%; Supplementary Table 1) . Genotyping of select variants, including those observed in single individuals, suggested that very few (<0.05%) of the genotype calls were incorrect (Online Methods).
In total, we identified 121 nonsynonymous variants across the seven genes ( Supplementary Fig. 6 and Supplementary Tables 2 and 3) . We omitted variants with minor allele frequency (MAF) >1% from our analyses, as they have been well studied in larger epidemiological cohorts 44, 45 . Following the model that is being used increasingly in sequence interpretation 7, 17 , we categorized the remaining 108 variants into four nonexclusive classes (Fig. 1, Table 2 and Online Methods): (i) low frequency nonsynonymous, resulting in altered protein sequence; (ii) possibly pathogenic, being located at an evolutionarily conserved site, private to one study individual and not observed in the 1000 Genomes project 46 , and computationally predicted as protein damaging by the mutation analysis tools SIFT 47 Despite the recognized limitations of meeting bioinformatics criteria alone for disease risk prediction 7, 50, 51 , variants similar to those in the HGMD MODY and putative pathogenic classes are likely to be reported from personal genome sequencing [52] [53] [54] [55] . Possibly pathogenic variants are also relevant in personal genomics, as they fit criteria that have been used to ascribe pathogenicity to variants identified by nextgeneration sequencing in Mendelian disease studies 56, 57 .
For validation, we applied these bioinformatic criteria to DNA sequence data obtained from 250 Norwegian patients fitting MODY diagnostic criteria ( Table 1 and Supplementary Fig. 7 ). In total, 48% of these patients carried variants meeting the low frequency nonsynonymous criteria (Supplementary Tables 4 and 5 22, 58 . We asked whether these variant carriers had clinical features that are associated with MODY (Online Methods): diabetes diagnosis ≤25 years (proband or family members), lean (body mass index (BMI) <25) and family history of diabetes (at least two generations; typically early onset) 13, 20, 59 . One variant carrier in the JHS cohort and no carriers in the FHS cohort fit these criteria (although several noncarriers did; Online Methods). These results suggest that only a small minority of individuals carrying such mutations demonstrate clinical characteristics that are consistent with MODY.
Despite not having signs of MODY, these variant carriers might nonetheless be at elevated risk for T2D or hyperglycemia. We calculated among these variant carriers the prevalence of diabetes (receiving medication for diabetes or fasting plasma glucose (FPG) levels >126 mg/dl) and impaired fasting glucose 60 (IFG; FPG of 100-126 mg/dl).
For carriers in the unselected cohorts, point estimates of risk for diabetes were not elevated relative to noncarriers ( Fig. 2a and Supplementary Table 6 ). Carriers of low frequency nonsynonymous variants showed no trend toward increased risk (FHS, odds ratio (OR) = 1.1; JHS, OR = 0.9; P > 0.1), with HGMD MODY or putative pathogenic variants having similar effect size estimates. The majority of variant carriers in these two classes (>90% of the FHS cohort and near 80% of the JHS cohort) did not develop diabetes, and only two of four carriers (50%) of variants in the most stringent putative pathogenic class developed diabetes (P = 0.049).
Furthermore, we did not observe a trend toward IFG in variant carriers ( Fig. 2b and Supplementary Table 6), despite many of these individuals being middle aged (Supplementary Fig. 8 ) and subjected to long-term follow up 14 . Only 32% of HGMD MODY variant carriers and 31% of proposed pathogenic variant carriers had IFG or diabetes (compared to ~35% of noncarriers). These results are consistent with previous reports showing a lack of association between PDX1 variation and diabetes 61 , although they apply more broadly across all seven genes analyzed.
We performed several additional analyses to investigate the observed low penetrance of variants in the unselected cohorts. First, to further validate our bioinformatics criteria, we computed carrier frequencies in the extreme T2D cohort (Supplementary Tables 5  and 7 ). Relative to the old obese controls, young lean cases with T2D carried a threefold excess of low frequency nonsynonymous variants (4.7% compared to 1.5%, OR = 3.2, P = 0.011) and an apparent excess of possibly pathogenic variants (four observations exclusive to cases, P = 0.04) or HGMD MODY variants (four case observations and one control observation). Absolute variant frequencies in the extreme cohort were not directly comparable to those in the unselected cohorts because of differences in ethnic composition. The relative frequencies between cases and controls, however, validate the ability of the bioinformatics criteria to identify an enrichment of rare mutations in not only individuals with MODY but also those with T2D, provided that these individuals are preselected for phenotype rather than being drawn at random from the population.
We next investigated whether analyzing multiple genes at once might influence our results, as MODY clinical presentation varies with the gene affected and the observed mutation 13, 20 . Whereas 64 individuals carried possibly pathogenic or HGMD MODY variants in the four most commonly mutated MODY genes, only four carried variants in INS, PDX1 or NEUROD1. Thus, inclusion of these three additional genes had a minimal impact on our results (Supplementary  Tables 8 and 9 ).
Next we analyzed variants specific to GCK, where mutations cause only mild and typically stable elevations in FPG (99-144 mg/dl compared to 72-108 mg/dl in normoglycemia) 20, 62 . Although only two carriers of low frequency nonsynonymous GCK mutations met the criteria for diabetes, 67% (8/12) had FPG levels ≥99 mg/dl (compared to 35% of noncarriers, combined P = 0.054; Fig. 3a and Supplementary Table 10 ). Thus, individuals who carry GCK variants may display mild hyperglycemia. This result would need to be precisely communicated in the clinic, as GCK-MODY is typically treated by diet modification alone 62 and does not show accelerated decline in beta-cell function 63 .
We then expanded the set of clinical readouts used in our analysis of specific genes. For HNF1A variant carriers, we asked whether glucose tolerance is affected even if FPG remains within the euglycemic range, a possibility suggested because HNF1A-MODY can demonstrate elevated fasting 2-h blood glucose increments (≥90 mg/dl) after an oral glucose tolerance test (OGTT) 63, 64 , and the common HNF1A c.293C>T (p.Ala98Val) variant is associated npg l e t t e r s with altered beta-cell function 65 . Only one of 17 HNF1A variant carriers had an elevated fasting 2-h glucose increment ( Fig. 3b and Supplementary Fig. 9 ). Likewise, HNF1B-MODY can be accompanied by renal dysfunction 34 ; none of the HNF1B variant carriers had abnormal creatinine values 66 ( Supplementary Fig. 10 ). In summary, a substantial proportion of individuals in the general population carry low frequency nonsynonymous variants in one of seven MODY genes. Two classes of bioinformatics criteria (either previously reported as causing MODY or rare, conserved and computationally predicted to be damaging) are each sufficient to identify a substantial enrichment of variants in individuals diagnosed with MODY or selected for an extreme diabetic phenotype. However, for each class, the majority of variant carriers observed in the general population remain euglycemic through middle age. These results highlight the limitations of disease variant databases, as well as objective and stringent bioinformatics criteria, in ascribing pathogenicity to rare variants.
Our study has multiple limitations. As the individuals were drawn from different genetic and environmental backgrounds, the frequencies and effect sizes are not directly comparable across cohorts. This reflects one of the potential challenges of personal genomics: the personal genome analyzed may not match the data sets from which effect size estimates are drawn. Also, because rare coding variants have low counts even in a study of thousands of participants, power is limited for the statistical assessment of heterogeneity across genes or variants; it is possible that a subset of the variants identified in fact have very large effects. Expert interpretation of each gene and variant, information about other family members and functional characterization of variants may identify a subset with large and robust effects, but these methods are not yet practical, let alone standardized 7 , in the automated analysis of personal genome sequences.
MODY is a useful model for studying the application of personal genome sequencing to disease risk prediction 13, 26 , as a number of causal genes have been well established, and a dominant pattern of inheritance predicts that heterozygous mutation carriers will have a phenotype. However, even for this one disease, extrapolation of effect size estimates from extreme individuals to unselected individuals (in the FHS and JHS cohorts) might falsely predict a substantial fraction as being at higher risk for diabetes: 3 in 200 individuals carry a variant that has been reported previously to cause MODY and yet exhibit no trend toward even late-onset T2D or IFG. Even objective bioinformatics criteria might incorrectly classify a considerable, although threefold lower, fraction of individuals as being at risk. The view that rare variants have deterministic effects, whereas common variants have modest effects, reflects in part the ascertainment bias of study designs used in Mendelian genetic research, as well as the true penetrance of rare mutations. 
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Sample selection. To obtain individuals for the unselected cohorts, we drew from the FHS Offspring cohort 14 and the JHS 15 cohort. As previously described, the FHS is a three-generation prospective, community-based, family study that began in 1948 and was designed to identify factors that contribute to cardiovascular disease 74 ; the Offspring cohort consists of 5,124 of the adult children and spouses (enrolled in 1971) of the original participants 14 . The JHS is a large, community-based, observational study whose participants were recruited from urban and rural areas of the Jackson, Mississippi, metropolitan statistical area 15 . These studies were performed using protocols approved by the FHS, JHS and Massachusetts Institute of Technology Institutional Review Board ethics committees and with informed consent from all participants.
To select individuals for the T2D cohort, we drew from 27,500 individuals in three prospective cohorts: the Malmö Preventive Project 75 (in Sweden), the Scania Diabetes Registry 76 (from Sweden) and the Botnia Study 77 (from Finland). Individuals were ranked according to a liability model that measured risk for T2D as described previously 11 . Briefly, liability scores were computed as the difference between diabetes status and the predicted risk based on age, BMI and gender; extreme cases were selected to have the highest liability scores (with diabetes but with low predicted risk for diabetes), and extreme controls were selected to have the lowest liability scores (without diabetes but with high predicted risk for diabetes). Individuals with an age of diabetes diagnosis below 35 years were excluded in an attempt to avoid consideration of patients with type 1 diabetes or MODY. The participants gave their written informed consent, and the study protocol was approved by the ethics committees of Helsinki University Hospital, Finland, and Lund University.
Clinical and phenotypic parameters in unselected cohorts. Phenotype information for the unselected cohorts was contained in the NHLBI Framingham cohort, dbGAP data set phs000007.v20.p8 (FHS), and the NHLBI Jackson Heart Study Candidate Gene Association Resource, dbGAP data set phs000286. v4.p1 (JHS). We used phenotypic data from exam 5 for individuals from the FHS and phenotypic data from exam 1 for individuals from the JHS.
Individuals were classified as having diabetes if they were documented as such in the FHS or JHS exams or had FPG levels ≥126 mg/dl. Individuals with FPG values 100-126 mg/dl were considered to display IFG. The euglycemic FPG range was consequently defined as 72-99 mg/dl (ref. 60). As patients with GCK-MODY exhibit only mildly elevated FPG levels as compared to other MODY subtypes, the FPG range fitting this specific phenotype was defined as 99-144 mg/dl (refs. 20,64) . For HNF1A variant carriers, aberrant fasting 2-h post-OGTT plasma glucose increments were defined as ≥90 mg/dl (this is indicative of beta-cell dysfunction) 64, 78 . HNF1B variant carriers were assessed for signs of renal dysfunction by evaluating serum creatinine levels, with the normal range being defined as 0.7-1.3 mg/dl (ref. 66) .
Sequencing, quality control and variant annotation. Although individuals in the T2D, FHS and JHS cohorts spanned multiple cohorts, all analyses (target capture, sequencing, variant calling, quality control, annotation and association analyses) were performed in an identical fashion using the same statistical pipeline. Patients with MODY were sequenced separately, but annotation and association were performed identically to the other three cohorts.
To sequence individuals in the T2D, FHS and JHS cohorts, we designed two custom hybrid capture arrays, each using the same previously described technology 43, 79 , to sequence two sets of genes as part of two larger studies. Individuals from the FHS and JHS cohorts were sequenced for 181 genes that have been associated previously with cardiovascular disease risk factors, including 37 genes that are associated with diabetes. Individuals from the T2D cohort were sequenced for 257 genes that have been associated previously with diabetes or heart attack (either identified through genome-wide associations or reported to cause Mendelian disorders). These arrays had in common nine genes that have been reported to harbor variants that cause MODY: the seven genes analyzed for this study, as well as ABCC8 and KCNJ11.
DNA libraries were bar coded using the Illumina index read strategy and sequenced with an Illumina HiSeq2000. Reads were mapped to the human genome hg19 with the BWA algorithm 80, 81 and processed with the Genome Analysis Toolkit (GATK) to recalibrate base-quality scores and perform local realignment around known insertions and deletions (indels) 82 . Target coverage for each sample was also computed with GATK. SNPs and small indels were called with the Unified Genotyper module of GATK and filtered to remove SNPs with annotations indicative of technical artifacts (such as strand bias, low variant call quality or homopolymer runs) 82 . SNPs with differential call rates (P < 1 × 10 −3 as computed by the PLINK software package 83 ) were excluded from association analyses. Variant calls from sequence data were deposited in dbGAP (FHS, data set phs000307.v5.p8; JHS, data set phs000498.v2.p1).
Samples were also genotyped on one of three genome-wide SNP arrays: the Affymetrix 500k GeneChip Mapping Set (FHS cohort), the Affymetrix Genome-Wide Human SNP Array 6.0 (JHS cohort) or the Metabochip (T2D cohort). We computed concordance of sequence genotypes with these SNP array genotypes using the PLINK software package 83 . Principal component analysis was performed on a set of SNPs common to all three platforms using PLINK and EIGENSTRAT 84 . These analyses verified that all individuals were unrelated (<25% of their genomes were identical by descent) and confirmed the distinct genetic background of each cohort (Supplementary Fig. 3 ). Quality control showed high (>96%) concordance between sequence and SNP array genotypes for the same individuals.
To ensure that all variants analyzed had genotypes that were strongly supported by sequence data, we used three strategies. First, we ignored all genotypes supported by fewer than ten reads (for example, set as 'missing'). Second, we examined the raw read data of every called variant and excluded from analysis any that had visual signatures of sequencing artifacts, such as reads of poor mapping quality, evidence for variation supported by only reads on one strand of the genome or additional called variants. Third, to evaluate the extent to which erroneous sequence genotypes might affect our analysis, we genotyped 143 SNPs called in the T2D cohort (the first cohort sequenced and with the lowest depth of coverage) using a Sequenom iPLEX Assay. This included 9 SNPs observed in only a single individual (singletons) and 27 SNPs observed in two individuals (doubletons). Of the 1,573 individuals identified as carrying one of these 143 SNPs on the basis of sequence genotypes, only 9 had different Sequenom genotypes (>99.4% nonreference concordance). All (100% of) the 63 identified carriers of singleton or doubleton variants were confirmed on the basis of Sequenom genotypes. These analyses collectively suggested that the analyzed genotypes were of high quality and that any errors had at most a minimal impact on our results.
We annotated variants previously reported to cause MODY using a list of mutations given in HGMD Professional v2012.1 (ref. 49) . Evolutionarily conserved variants were defined as those at sites conserved across 46 vertebrates on the basis of PhyloP scores (log 10 odds (LOD) >3) downloaded from the UCSC genome browser database 85 . Rare variants were defined as those observed in only a single study individual across the T2D, FHS and JHS cohorts and were also not identified as part of the 1000 Genomes project 46 . Predicted protein-damaging variants were defined as those that were either deleterious according to SIFT 47 and possibly or probably damaging according to Polyphen-2 (ref. 48) or nonsense, frame-shift or essential splice-site mutations according to the Variant Effect Predictor 67 . Protein and nucleotide changes, and SIFT and Polyphen-2 scores, were produced for each variant with the Variant Effect Predictor using the biologically relevant transcripts for each gene (as listed in the HGMD and shown in the accession codes section).
For analyses that required variants below a given frequency, variants that exceeded the threshold in any of the cohorts were removed from analysis.
Analysis of patients with MODY. As a technical validation of the annotation protocol used for the population-based cohorts, variants in 250 subjects with MODY were analyzed using the same methodology. As previously described 21, 36, [86] [87] [88] [89] [90] [91] [92] [93] , subjects with MODY were recruited from the Norwegian MODY Registry, a national, population-based registry that was established in 1997. Patients are referred to the registry if they fit the following criteria: (i) a first-degree relative with diabetes; (ii) onset of diabetes before age 25 years in at least one family member; (iii) a low-dose insulin requirement; or (iv) unusual type 1 diabetes (insulin requirement below 0.5 U per kg per d, no antibodies or atypical history). The four most common MODY genes (HNF1A, HNF4A, GCK and INS) are routinely sequenced in the first instance. If fasting glucose levels are >100 mg/dl and the hemoglobin A1c (HbA1c) percentage is less than 7.5% in an individual, GCK is investigated first, followed by the other genes from the list above. If renal cysts or renal failure presents before npg diabetes, HNF1B is investigated. NEUROD1 and PDX1 were investigated as part of a screening program and are not routinely tested. Informed consent was obtained from all participants, and the study was approved by the Regional Committee for Research Ethics and the Norwegian Data Inspectorate.
To screen patients, genomic DNA was first extracted from peripheral leukocytes using standard procedures. The coding exons and intron-exon boundaries of HNF1A, HNF4A, GCK, HNF1B, PDX1, NEUROD1 and INS were then PCR amplified and sequenced using an Applied Biosystems 3730 capillary sequencer (Applied Biosystems, Foster City, CA). We imported the samples into the SeqScape Software (Applied Biosystems) and analyzed them for sequence variations by comparison with published reference sequences (NM_000545.5, NM_175914.3, NM_000162.3, NM_000458.2, NM_000209.3, NM_002500.3 and NM_000207.2). Variants were annotated and classified using the same procedure as for the three population-based cohorts.
Assessment of MODY-relevant clinical criteria in unselected cohorts. We examined variant carriers in the FHS and JHS cohorts to see whether any fit the following phenotypic criteria that are associated with MODY: diabetes diagnosis at ≤25 years of age (for the proband or family members), lean (BMI <25) and family history of diabetes (at least two generations; typically early onset). We did not have access to age of diabetes diagnosis for all family members and thus could only examine the diagnosis age of variant carriers.
In the FHS cohort, no variant carriers simultaneously fit the criteria for early diabetes diagnosis and low BMI (4/116 variant carriers had diabetes with BMI below 25, but each had age of onset above 55 years, and only one variant carrier had BMI below 30 and age of onset below 40 years). The frequency of carriers fitting these criteria was thus comparable to that for noncarriers: one of the 1,349 noncarriers had BMI below 25 and age of onset below 30 years, whereas eight had BMI below 30 and age of onset below 40 years.
In the JHS cohort, 1/235 variant carriers had a family history of diabetes, age of onset ≤25 years and a BMI of 29.8; the rest had BMI above 30 or age of onset above 42 years. Similar to the FHS cohort, the frequency of carriers fitting these criteria was similar to that for noncarriers: two of the 1,405 noncarriers had a family history of diabetes, age of onset below 25 years and BMI below 25, with four more having a family history, age of onset below 40 years and BMI below 30.
Statistical analyses.
We tested for association between phenotype (whether extreme T2D status, diabetes, IFG or a gene-specific phenotype) and variant carrier status using the Cochran-Mantel-Haenszel test as implemented in the PLINK software package 83 . Randomized permutation of phenotypes was used to obtain one-sided P values. For the T2D cohort, stratified permutation of phenotypes (separately for individuals of Finnish and Swedish descent) was used to control for ethnic differences across individuals; because of the small number of variant counts in this cohort, further investigation of population stratification was statistically challenging. For the unselected cohorts, tests were first run separately for individuals from each of the FHS and JHS cohorts and then jointly for individuals from both cohorts (with stratified permutation of phenotypes within cohort) to obtain combined P values in all figures or tables (including Fig. 2) . For all figures, confidence intervals were obtained by the Clopper-Pearson method as implemented in the R software package.
